Diagnosis_NN and_CC Management_NN of_IN Human_NP Cytomegalovirus_NP Infection_NP in_IN the_DT Mother_NP ,_, Fetus_NP ,_, and_CC Newborn_NP Infant_NP Human_NP cytomegalovirus_NN (_( HCMV_NP )_) is_VBZ the_DT leading_VBG cause_NN of_IN congenital_JJ viral_JJ infection_NN and_CC mental_JJ retardation_NN ._SENT HCMV_NP infection_NN ,_, while_IN causing_VBG asymptomatic_JJ infections_NNS in_IN most_JJS immunocompetent_JJ subjects_NNS ,_, can_MD be_VB transmitted_VBN during_IN pregnancy_NN from_IN the_DT mother_NN with_IN primary_NN (_( and_CC also_RB recurrent_JJ )_) infection_NN to_TO the_DT fetus_NN ._SENT Hence_RB ,_, careful_JJ diagnosis_NN of_IN primary_JJ infection_NN is_VBZ required_VBN in_IN the_DT pregnant_JJ woman_NN based_VBN on_IN the_DT most_RBS sensitive_JJ serologic_JJ assays_NNS (_( immunoglobulin_NN M_NP [_SYM IgM_NP ]_SYM and_CC IgG_NP avidity_NN assays_NNS )_) and_CC conventional_JJ virologic_JJ and_CC molecular_JJ procedures_NNS for_IN virus_NN detection_NN in_IN blood_NN ._SENT Maternal_JJ prognostic_JJ markers_NNS of_IN fetal_JJ infection_NN are_VBP still_RB under_IN investigation_NN ._SENT If_IN primary_JJ infection_NN is_VBZ diagnosed_VBN in_IN a_DT timely_JJ manner_NN ,_, prenatal_JJ diagnosis_NN can_MD be_VB offered_VBN ,_, including_VBG the_DT search_NN for_IN virus_NN and_CC virus_NN components_NNS in_IN fetal_JJ blood_NN and_CC amniotic_JJ fluid_NN ,_, with_IN fetal_JJ prognostic_JJ markers_NNS of_IN HCMV_NP disease_NN still_RB to_TO be_VB defined_VBN ._SENT However_RB ,_, the_DT final_JJ step_NN for_IN definite_JJ diagnosis_NN of_IN congenital_JJ HCMV_NP infection_NN is_VBZ detection_NN of_IN virus_NN in_IN the_DT blood_NN or_CC urine_NN in_IN the_DT first_JJ 1_CD to_TO 2_CD weeks_NNS of_IN life_NN ._SENT To_TO date_NN ,_, treatment_NN of_IN congenital_JJ infection_NN with_IN antiviral_JJ drugs_NNS is_VBZ only_RB palliative_JJ both_CC prior_JJ to_TO and_CC after_IN birth_NN ,_, whereas_IN the_DT only_RB efficacious_JJ preventive_JJ measure_NN seems_VBZ to_TO be_VB the_DT development_NN of_IN a_DT safe_JJ and_CC immunogenic_JJ vaccine_NN ,_, including_VBG recombinant_JJ ,_, subunit_NN ,_, DNA_NP ,_, and_CC peptide-based_JJ vaccines_NNS now_RB under_IN investigation_NN ._SENT The_DT following_VBG controversial_JJ issues_NNS are_VBP discussed_VBN in_IN the_DT light_NN of_IN the_DT most_RBS recent_JJ advances_NNS in_IN the_DT field_NN :_: the_DT actual_JJ perception_NN of_IN the_DT problem_NN ;_: universal_JJ serologic_JJ screening_NN before_IN pregnancy_NN ;_: the_DT impact_NN of_IN correct_JJ counseling_NN on_IN decision_NN making_VBG by_IN the_DT couple_NN involved_VBN ;_: the_DT role_NN of_IN prenatal_JJ diagnosis_NN in_IN ascertaining_VBG transmission_NN of_IN virus_NN to_TO the_DT fetus_NN ;_: the_DT impact_NN of_IN preconceptional_JJ and_CC periconceptional_JJ infections_NNS on_IN the_DT prevalence_NN of_IN congenital_JJ infection_NN ;_: and_CC the_DT prevalence_NN of_IN congenitally_RB infected_JJ babies_NNS born_VBN to_TO mothers_NNS who_WP were_VBD immune_JJ prior_RB to_TO pregnancy_NN compared_VBN to_TO the_DT number_NN born_VBN to_TO mothers_NNS undergoing_VBG primary_JJ infection_NN during_IN pregnancy_NN ._SENT Human_JJ cytomegalovirus_NN (_( HCMV_NP )_) is_VBZ the_DT vernacular_JJ name_NN of_IN human_JJ herpesvirus_NP 5_CD ,_, a_DT highly_RB host-specific_JJ virus_NN of_IN the_DT Herpesviridae_NP family_NN ._SENT HCMV_NP is_VBZ the_DT largest_JJS virus_NN in_IN the_DT family_NN and_CC is_VBZ morphologically_RB indistinguishable_JJ from_IN other_JJ human_JJ herpesviruses_NNS ._SENT HCMV_NP ,_, like_IN all_DT herpesviruses_NNS ,_, undergoes_VBZ latency_NN and_CC reactivation_NN in_IN the_DT host_NN ._SENT Although_IN HCMV_NP has_VBZ been_VBN shown_VBN to_TO infect_VB a_DT broad_JJ spectrum_NN of_IN cells_NNS in_IN vivo_RB ,_, the_DT only_JJ cells_NNS that_WDT are_VBP fully_RB permissive_JJ for_IN HCMV_NP replication_NN in_IN vitro_NN are_VBP human_JJ fibroblasts_NNS ._SENT In_IN these_DT cells_NNS ,_, virus_NN replication_NN results_NNS in_IN the_DT formation_NN of_IN intranuclear_JJ and_CC intracytoplasmic_JJ inclusion_NN bodies_NNS ,_, with_IN the_DT former_JJ full_JJ of_IN nucleocapsids_NNS and_CC the_DT latter_NN containing_VBG several_JJ dense_JJ bodies_NNS ._SENT Nucleocapsids_NNS acquire_VB the_DT envelope_NN from_IN the_DT nuclear_JJ membrane_NN or_CC cytoplasmic_JJ vacuoles_NNS ._SENT HCMV_NP is_VBZ a_DT virus_NN of_IN paradoxes_NNS ._SENT It_PP can_MD be_VB a_DT potential_JJ killer_NN or_CC a_DT lifelong_JJ silent_JJ companion_NN ._SENT These_DT two_CD aspects_NNS are_VBP confirmed_VBN in_IN an_DT exemplary_JJ manner_NN by_IN the_DT circumstances_NNS ,_, vividly_RB reviewed_VBN by_IN Thomas_NP H_NP Weller_NP ,_, surrounding_VBG the_DT isolation_NN of_IN the_DT first_JJ HCMV_NP strains_NNS ._SENT In_IN 1956_CD ,_, Margaret_NP G._NP Smith_NP recovered_VBD the_DT first_JJ HCMV_NP isolate_NN from_IN the_DT submaxillary_JJ salivary_JJ gland_NN tissue_NN of_IN a_DT dead_JJ infant_NN and_CC the_DT second_JJ isolate_NN from_IN the_DT kidney_NN tissue_NN of_IN a_DT baby_NN dying_VBG of_IN cytomegalic_JJ inclusion_NN disease_NN ._SENT The_DT same_JJ year_NN ,_, Rowe_NP and_CC coworkers_NNS ,_, who_WP recovered_VBD adenoviruses_NNS by_IN observing_VBG cytopathic_JJ changes_NNS in_IN uninoculated_JJ cultures_NNS of_IN human_JJ adenoids_NN ,_, noted_VBD unique_JJ focal_JJ lesions_NNS and_CC intranuclear_JJ inclusions_NNS primarily_RB in_IN the_DT fibroblast_NN component_NN of_IN cultures_NNS of_IN adenoidal_JJ tissues_NNS from_IN three_CD asymptomatic_JJ children_NNS ._SENT The_DT cytopathic_JJ effect_NN of_IN the_DT new_JJ virus_NN strain_NN (_( AD169_NP )_) very_RB closely_RB resembled_VBD that_IN of_IN the_DT Davis_NP strain_NN that_WDT was_VBD observed_VBN 1_CD year_NN later_RBR by_IN Weller_NP and_CC colleagues_NNS in_IN human_JJ embryonic_JJ skin_NN muscle_NN tissue_NN cultures_NNS inoculated_VBN with_IN a_DT liver_NN biopsy_NN taken_VBN from_IN a_DT 3-month-old_JJ infant_NN with_IN microcephaly_NN ,_, jaundice_NN ,_, hepatosplenomegaly_RB ,_, chorioretinitis_NN ,_, and_CC cerebral_JJ calcifications_NNS ._SENT The_DT same_JJ group_NN of_IN researchers_NNS isolated_VBD two_CD additional_JJ HCMV_NP strains_NNS :_: the_DT Kerr_NP strain_NN from_IN the_DT urine_NN of_IN a_DT newborn_NN with_IN petechiae_NNS ,_, hepatosplenomegaly_RB ,_, and_CC jaundice_NN ,_, and_CC the_DT Esp_NP ._SENT strain_NN from_IN the_DT urine_NN of_IN an_DT infant_NN with_IN hepatosplenomegaly_JJ ,_, periventricular_JJ calcification_NN ,_, and_CC chorioretinitis_NN ._SENT In_IN the_DT following_VBG years_NNS ,_, HCMV_NP also_RB showed_VBD its_PP$ pathogenic_JJ properties_NNS in_IN organ_NN transplant_NN recipients_NNS ,_, patients_NNS with_IN AIDS_NP ,_, and_CC cancer_NN patients_NNS ,_, while_IN it_PP gained_VBD the_DT leading_VBG position_NN among_IN infectious_JJ agents_NNS responsible_JJ for_IN mental_JJ retardation_NN ,_, intellectual_JJ impairment_NN ,_, and_CC deafness_NN ._SENT Presently_RB ,_, HCMV_NP infection_NN is_VBZ mostly_RB controlled_VBN in_IN immunocompromised_JJ patients_NNS by_IN available_JJ antiviral_JJ drugs_NNS ,_, yet_CC it_PP continues_VBZ to_TO maintain_VB its_PP$ role_NN as_IN the_DT most_RBS dangerous_JJ infectious_JJ agent_NN for_IN the_DT unborn_JJ infant_NN ._SENT Thus_RB ,_, HCMV_NP infection_NN is_VBZ still_RB a_DT major_JJ health_NN problem_NN ,_, warranting_VBG strong_JJ preventive_JJ measures_NNS ._SENT The_DT major_JJ scope_NN of_IN this_DT review_NN will_MD be_VB to_TO analyze_VB and_CC update_VB the_DT diagnostic_JJ and_CC prognostic_JJ implications_NNS of_IN primary_JJ HCMV_NP infections_NNS in_IN pregnancy_NN in_IN the_DT mother_NN ,_, fetus_NN ,_, and_CC newborn_JJ ._SENT Special_JJ emphasis_NN will_MD be_VB given_VBN to_TO less-investigated_JJ issues_NNS ,_, such_JJ as_IN detection_NN of_IN virus_NN and_CC viral_JJ products_NNS in_IN the_DT blood_NN of_IN the_DT mother_NN during_IN primary_JJ HCMV_NP infection_NN ,_, the_DT presence_NN of_IN clinical_JJ signs_NNS and_CC symptoms_NNS in_IN the_DT mother_NN ,_, prenatal_JJ diagnosis_NN of_IN congenital_JJ infection_NN in_IN amniotic_JJ fluid_NN and_CC fetal_JJ blood_NN ,_, maternal_JJ and_CC fetal_JJ prognostic_JJ markers_NNS of_IN HCMV_NP infection_NN and_CC disease_NN ,_, and_CC the_DT impact_NN of_IN counseling_NN ._SENT Measures_NNS of_IN treatment_NN and_CC prevention_NN of_IN congenital_JJ HCMV_NP infection_NN will_MD be_VB mentioned_VBN briefly_RB ._SENT The_DT last_JJ part_NN of_IN the_DT review_NN will_MD deal_VB with_IN the_DT most_RBS controversial_JJ issues_NNS ,_, in_IN particular_JJ ,_, how_WRB the_DT problem_NN of_IN HCMV_NP infections_NNS in_IN pregnancy_NN is_VBZ perceived_VBN by_IN the_DT scientific_JJ community_NN and_CC public_JJ health_NN authorities_NNS ._SENT Is_VBZ preconception_NN serologic_JJ screening_NN justified_VBN ,_, and_CC should_MD HCMV-seronegative_JJ women_NNS be_VB prospectively_RB monitored_VBN ?_SENT What_WP are_VBP the_DT limits_NNS of_IN prenatal_JJ diagnosis_NN (_( false-positive_JJ and_CC false-negative_JJ results_NNS )_) ?_SENT What_WP is_VBZ the_DT role_NN of_IN preconceptional_JJ and_CC periconceptional_JJ infections_NNS in_IN HCMV_NP transmission_NN to_TO the_DT fetus_NN ?_SENT Are_VBP reactivated_VBN infections_NNS significant_JJ in_IN transmission_NN of_IN virus_NN to_TO the_DT fetus_NN ?_SENT Finally_RB ,_, one_CD additional_JJ goal_NN is_VBZ to_TO focus_VB the_DT attention_NN of_IN the_DT scientific_JJ community_NN on_IN the_DT problem_NN of_IN congenital_JJ HCMV_NP infection_NN and_CC to_TO appeal_VB for_IN international_JJ collaboration_NN ._SENT We_PP truly_RB need_VBP to_TO develop_VB and_CC implement_VB consensus_NN strategies_NNS for_IN prevention_NN of_IN congenital_JJ HCMV_NP infection_NN ,_, ideally_RB through_IN a_DT vaccine_NN ._SENT FIG._NN 1_CD ._SENT |_SYM HCMV_NP replication_NN in_IN human_JJ embryonic_JJ lung_NN fibroblast_NN cell_NN cultures_NNS ._SENT HCMV_NP replication_NN in_IN human_JJ embryonic_JJ lung_NN fibroblast_NN cell_NN cultures_NNS ._SENT (_( A_NP )_) HCMV-infected_JJ human_JJ fibroblast_NN 120_CD h_NN postinfection_NN (_( following_VBG immunoperoxidase_NN staining_VBG with_IN human_JJ antibodies_NNS )_) ,_, showing_VBG intranuclear_JJ (_( IN_IN )_) and_CC intracytoplasmic_JJ (_( IC_NP )_) inclusion_NN bodies_NNS ._SENT (_( B_NP to_TO D_NP )_) Electron_NP microscopy_NN of_IN HCMV-infected_JJ human_JJ fibroblasts_NNS ._SENT (_( B_LS )_) Horseshoe-shaped_JJ intranuclear_JJ inclusion_NN (_( IN_IN )_) ._SENT (_( C_NP )_) Dense_NP bodies_NNS (_( arrows_NNS )_) ._SENT (_( D_NP )_) Maturing_NP virus_NN particles_NNS at_IN the_DT level_NN of_IN the_DT nuclear_JJ membrane_NN ._SENT The_DT term_NN vertical_JJ transmission_NN is_VBZ used_VBN here_RB to_TO indicate_VB HCMV_NP transmission_NN from_IN mother_NN to_TO fetus_NN during_IN pregnancy_NN ,_, thus_RB excluding_VBG virus_NN transmission_NN from_IN mother_NN to_TO newborn_JJ infant_NN ._SENT Due_JJ to_TO latency_NN following_VBG primary_JJ infection_NN and_CC periodic_JJ reactivation_NN of_IN HCMV_NP replication_NN causing_VBG recurrent_JJ infections_NNS ,_, in_IN utero_NP transmission_NN of_IN HCMV_NP may_MD follow_VB either_DT primary_JJ or_CC recurrent_JJ infections_NNS ._SENT It_PP is_VBZ commonly_RB recognized_VBN that_IN primary_JJ HCMV_NP infections_NNS are_VBP transmitted_VBN more_RBR frequently_RB to_TO the_DT fetus_NN and_CC are_VBP more_RBR likely_JJ to_TO cause_VB fetal_JJ damage_NN than_IN recurrent_JJ infections_NNS ._SENT In_IN addition_NN ,_, it_PP seems_VBZ that_IN primary_JJ infection_NN occurring_VBG at_IN an_DT earlier_RBR gestational_JJ age_NN is_VBZ related_VBN to_TO a_DT worse_JJR outcome_NN ._SENT Initially_RB ,_, the_DT role_NN of_IN recurrent_JJ maternal_JJ infections_NNS in_IN causing_VBG congenital_JJ infections_NNS was_VBD supported_VBN by_IN three_CD independent_JJ reports_NNS describing_VBG congenital_JJ infections_NNS in_IN consecutive_JJ pregnancies_NNS ._SENT In_IN all_DT three_CD reports_NNS ,_, the_DT first_JJ newborn_NN was_VBD severely_RB affected_VBN and_CC the_DT second_JJ one_CD was_VBD subclinically_RB infected_VBN ._SENT Molecular_JJ epidemiological_JJ studies_NNS indicated_VBD that_IN in_IN each_DT of_IN three_CD pairs_NNS of_IN congenitally_RB infected_JJ siblings_NNS ,_, the_DT viruses_NNS were_VBD identical_JJ to_TO each_DT other_JJ when_WRB examined_VBN by_IN restriction_NN fragment_NN length_NN polymorphism_NN analysis_NN ._SENT However_RB ,_, the_DT first_JJ convincing_JJ evidence_NN of_IN the_DT possible_JJ transmission_NN of_IN HCMV_NP from_IN immune_JJ mothers_NNS to_TO the_DT fetus_NN came_VBD from_IN a_DT prospective_JJ study_NN showing_VBG that_IN 10_CD congenitally_RB infected_JJ infants_NNS were_VBD born_VBN to_TO immune_JJ mothers_NNS within_IN a_DT group_NN of_IN 541_CD infants_NNS of_IN women_NNS who_WP were_VBD seropositive_JJ before_IN pregnancy_NN ,_, with_IN a_DT prevalence_NN of_IN 1.9_CD %_NN ._SENT Subsequently_RB ,_, similar_JJ findings_NNS were_VBD observed_VBN in_IN a_DT geographic_JJ area_NN where_WRB nearly_RB the_DT entire_JJ population_NN was_VBD immune_JJ to_TO HCMV_NP during_IN childhood_NN ,_, and_CC the_DT prevalence_NN of_IN congenital_JJ infection_NN was_VBD found_VBN to_TO be_VB 1.4_CD %_NN ._SENT In_IN 1985_CD ,_, Stagno_NP and_CC Whitley_NP estimated_VBD the_DT maternal_JJ risk_NN of_IN acquiring_VBG either_DT primary_JJ or_CC recurrent_JJ HCMV_NP infection_NN in_IN pregnancy_NN as_RB well_RB as_IN the_DT risk_NN of_IN intrauterine_JJ transmission_NN to_TO the_DT offspring_NN in_IN two_CD groups_NNS of_IN women_NNS of_IN low_JJ or_CC high_JJ socioeconomic_JJ status_NN ._SENT Their_PP$ estimates_NNS showed_VBD that_IN the_DT risk_NN of_IN primary_JJ maternal_JJ infection_NN was_VBD about_RB three_CD times_NNS higher_JJR among_IN the_DT higher-income_JJ susceptible_JJ women_NNS (_( 45_CD %_NN )_) ,_, compared_VBN to_TO 15_CD %_NN in_IN the_DT lower-income_JJ group_NN ._SENT In_IN both_DT groups_NNS ,_, transmission_NN to_TO the_DT fetus_NN occurred_VBD in_IN about_RB 40_CD %_NN of_IN cases_NNS ,_, with_IN delivery_NN of_IN about_RB 10_CD to_TO 15_CD %_NN symptomatic_JJ and_CC 85_CD to_TO 90_CD %_NN asymptomatic_JJ congenitally_RB infected_JJ newborns_NNS ._SENT Among_IN the_DT asymptomatic_JJ newborns_NNS ,_, about_RB 10_CD %_NN developed_VBN sequelae_NNS ,_, while_IN about_RB 90_CD %_NN of_IN infants_NNS that_WDT were_VBD asymptomatic_JJ at_IN birth_NN developed_VBN normally_RB ._SENT On_IN the_DT other_JJ hand_NN ,_, the_DT rate_NN of_IN congenital_JJ infections_NNS from_IN recurrent_JJ maternal_JJ infection_NN was_VBD 0.15_CD %_NN in_IN the_DT higher-income_JJ group_NN of_IN pregnant_JJ women_NNS ,_, who_WP were_VBD 55_CD %_NN immune_JJ ,_, and_CC 0.5_CD to_TO 1_CD %_NN in_IN the_DT lower-income_JJ group_NN ,_, which_WDT was_VBD 85_CD %_NN immune_NN ,_, i.e._FW ,_, 3_CD to_TO 7_CD times_NNS higher_RBR ._SENT However_RB ,_, the_DT rate_NN of_IN clinically_RB apparent_JJ disease_NN was_VBD low_JJ and_CC similar_JJ (_( 0_CD to_TO 1_CD %_NN )_) in_IN both_DT groups_NNS ._SENT It_PP is_VBZ currently_RB accepted_VBN that_IN congenital_JJ HCMV_NP infection_NN may_MD be_VB the_DT consequence_NN of_IN either_CC a_DT primary_JJ or_CC recurrent_JJ maternal_JJ infection_NN ._SENT Recurrent_JJ infections_NNS may_MD consist_VB of_IN either_DT reactivation_NN of_IN the_DT virus_NN strain_NN causing_VBG primary_JJ infection_NN or_CC reinfection_NN by_IN a_DT new_JJ virus_NN strain_NN ._SENT Recently_RB ,_, the_DT incidence_NN of_IN symptomatic_JJ congenital_JJ HCMV_NP infections_NNS in_IN immune_JJ mothers_NNS has_VBZ been_VBN shown_VBN to_TO be_VB similar_JJ in_IN primary_JJ and_CC recurrent_JJ maternal_JJ infections_NNS ._SENT In_IN addition_NN ,_, symptomatic_JJ congenital_JJ infections_NNS appear_VBP to_TO be_VB mostly_RB caused_VBN by_IN reinfection_NN of_IN immune_JJ mothers_NNS during_IN pregnancy_NN by_IN a_DT new_JJ HCMV_NP strain_NN ._SENT This_DT conclusion_NN was_VBD based_VBN on_IN demonstration_NN of_IN the_DT appearance_NN of_IN antibodies_NNS directed_VBN against_IN new_JJ epitopes_NNS of_IN glycoprotein_NN H_NN of_IN HCMV_NP not_RB present_JJ in_IN the_DT blood_NN prior_RB to_TO the_DT current_JJ pregnancy_NN ._SENT Sequencing_VBG of_IN the_DT glycoprotein_NN H_NN gene_NN has_VBZ confirmed_VBN the_DT presence_NN of_IN a_DT new_JJ virus_NN strain_NN in_IN the_DT reported_VBN cases_NNS ._SENT On_IN the_DT other_JJ hand_NN ,_, congenital_JJ infections_NNS following_VBG reactivated_VBN maternal_JJ infection_NN are_VBP mostly_RB asymptomatic_JJ ._SENT In_IN conclusion_NN ,_, the_DT true_JJ frequency_NN and_CC clinical_JJ importance_NN of_IN congenital_JJ HCMV_NP infections_NNS from_IN recurrent_JJ maternal_JJ infections_NNS remain_VBP to_TO be_VB determined_VBN in_IN long-term_JJ prospective_JJ studies_NNS ._SENT However_RB ,_, primary_JJ HCMV_NP infection_NN continues_VBZ to_TO be_VB the_DT major_JJ viral_JJ cause_NN of_IN congenital_JJ infections_NNS ,_, with_IN significant_JJ morbidity_NN ._SENT Recent_JJ findings_NNS related_VBN to_TO the_DT potential_JJ role_NN of_IN recurrent_JJ maternal_JJ infection_NN in_IN symptomatic_JJ congenital_JJ infection_NN complicate_VB but_CC will_MD not_RB interfere_VB with_IN efforts_NNS aimed_VBN at_IN developing_VBG a_DT safe_JJ and_CC efficacious_JJ vaccine_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Characteristics_NP of_IN HCMV_NP infection_NN in_IN pregnancy_NN ._SENT Characteristics_NNS of_IN HCMV_NP infection_NN in_IN pregnancy_NN ._SENT (_( From_IN S._NP Stagno_NP and_CC R._NP J._NP Whitley_NP ,_, used_VBN with_IN permission_NN ._SENT )_) In_IN the_DT case_NN of_IN primary_JJ maternal_JJ infection_NN ,_, the_DT antiviral_JJ immune_JJ response_NN begins_VBZ proximate_JJ to_TO virus_NN transmission_NN to_TO the_DT fetus_NN ,_, whereas_IN in_IN the_DT case_NN of_IN recurrent_JJ infection_NN ,_, virus_NN transmission_NN occurs_VBZ in_IN the_DT presence_NN of_IN both_DT humoral_JJ and_CC cell-mediated_JJ immune_JJ responses_NNS ._SENT As_IN a_DT result_NN ,_, viremia_NN occurs_VBZ as_IN a_DT rule_NN only_RB in_IN primary_JJ infections_NNS ,_, whereas_IN it_PP is_VBZ either_RB absent_JJ or_CC undetectable_JJ in_IN recurrent_JJ infections_NNS of_IN the_DT immunocompetent_JJ host_NN and_CC common_JJ in_IN recurrent_JJ infections_NNS of_IN immunocompromised_JJ patients_NNS ._SENT Since_RB ,_, following_VBG primary_JJ HCMV_NP infection_NN ,_, intrauterine_JJ transmission_NN occurs_VBZ in_IN only_RB 30_CD to_TO 40_CD %_NN of_IN cases_NNS ,_, an_DT innate_JJ barrier_NN seems_VBZ to_TO partially_RB prevent_VB vertical_JJ transmission_NN ._SENT In_IN addition_NN ,_, a_DT similar_JJ event_NN seems_VBZ to_TO occur_VB among_IN infected_JJ newborns_NNS ,_, less_JJR than_IN 15_CD %_NN of_IN whom_WP show_VBP clinically_RB apparent_JJ infection_NN ,_, in_IN the_DT great_JJ majority_NN of_IN cases_NNS resulting_VBG from_IN primary_JJ maternal_JJ infection_NN ._SENT Finally_RB ,_, in_IN reactivated_VBN maternal_JJ infections_NNS ,_, the_DT risk_NN of_IN symptomatic_JJ congenital_JJ infection_NN is_VBZ even_RB markedly_RB lower_JJR ,_, as_RB shown_VBN by_IN the_DT few_JJ symptomatic_JJ infants_NNS reported_VBN in_IN the_DT past_JJ to_TO have_VB been_VBN born_VBN to_TO mothers_NNS who_WP were_VBD immune_JJ before_IN pregnancy_NN ._SENT In_IN fact_NN ,_, although_IN existing_VBG immunity_NN does_VBZ not_RB prevent_VB transmission_NN of_IN the_DT virus_NN to_TO the_DT fetus_NN ,_, reactivated_VBD infections_NNS are_VBP less_RBR likely_JJ to_TO cause_VB damage_NN to_TO the_DT offspring_NN than_IN primary_JJ infections_NNS ._SENT Multiple_JJ mechanisms_NNS of_IN immune_JJ evasion_NN for_IN HCMV_NP could_MD relate_VB to_TO the_DT pathogenic_JJ role_NN of_IN the_DT virus_NN ._SENT Recently_RB ,_, expression_NN of_IN immune_JJ evasion_NN genes_NNS US3_NP ,_, US6_NP ,_, and_CC US11_NP of_IN HCMV_NP in_IN the_DT blood_NN of_IN solid_JJ organ_NN transplant_NN recipients_NNS has_VBZ been_VBN investigated_VBN ,_, showing_VBG that_IN ,_, after_IN clinical_JJ recovery_NN ,_, transcripts_NNS of_IN these_DT genes_NNS remain_VBP detectable_JJ ,_, indicating_VBG that_IN persistent_JJ low_JJ viral_JJ activity_NN may_MD have_VB implications_NNS for_IN long-term_JJ control_NN of_IN HCMV_NP infection_NN ._SENT Little_RB is_VBZ still_RB known_VBN about_IN the_DT mechanisms_NNS of_IN HCMV_NP transmission_NN to_TO the_DT fetus_NN ._SENT It_PP has_VBZ been_VBN reported_VBN that_IN about_RB 15_CD %_NN of_IN women_NNS undergoing_VBG primary_JJ infection_NN during_IN the_DT first_JJ months_NNS of_IN pregnancy_NN abort_VBP spontaneously_RB ,_, showing_VBG placental_JJ but_CC not_RB fetal_JJ infection_NN ._SENT Subsequently_RB in_IN the_DT course_NN of_IN pregnancy_NN ,_, placental_JJ infection_NN has_VBZ been_VBN shown_VBN to_TO be_VB consistently_RB associated_VBN with_IN fetal_JJ infection_NN ._SENT Understanding_VBG the_DT mechanisms_NNS of_IN HCMV_NP transmission_NN to_TO the_DT fetus_NN implies_VBZ elucidation_NN of_IN some_DT major_JJ steps_NNS in_IN placental_JJ development_NN ._SENT The_DT development_NN of_IN the_DT placenta_NN requires_VBZ differentiation_NN of_IN specialized_JJ epithelial_JJ stem_NN cells_NNS ,_, referred_VBD to_TO as_IN cytotrophoblasts_NNS ,_, in_IN both_DT floating_JJ villi_NNS ,_, where_WRB they_PP fuse_VBP into_IN multinucleate_JJ syncytiotrophoblasts_NNS covering_VBG the_DT villous_JJ surface_NN ,_, and_CC anchoring_VBG villi_NNS ,_, where_WRB they_PP aggregate_VBP into_IN columns_NNS of_IN single_JJ cells_NNS invading_VBG the_DT endometrium_NN and_CC the_DT first_JJ third_NN of_IN the_DT myometrium_NN (_( interstitial_JJ invasion_NN )_) ._SENT While_IN the_DT syncytiotrophoblast_NN is_VBZ in_IN direct_JJ contact_NN with_IN maternal_JJ blood_NN ,_, mediating_VBG transport_NN of_IN multiple_JJ substances_NNS to_TO and_CC from_IN the_DT fetus_NN ,_, the_DT cytotrophoblast_NN columns_NNS also_RB invade_VBP maternal_JJ arterioles_NNS (_( endovascular_JJ invasion_NN )_) by_IN replacing_VBG endothelial_JJ and_CC smooth_JJ muscle_NN cells_NNS and_CC thus_RB generating_VBG a_DT hybrid_JJ cell_NN population_NN of_IN fetal_JJ and_CC maternal_JJ cells_NNS inside_IN uterine_JJ vessels_NNS ._SENT Syncytiotrophoblasts_NNS upregulate_VBP expression_NN of_IN the_DT neonatal_JJ immunoglobulin_NN G_NP (_( IgG_NP )_) Fc_NP receptor_NN ,_, involved_VBN in_IN transport_NN of_IN maternal_JJ IgG_NP to_TO the_DT fetus_NN ._SENT In_IN parallel_NN ,_, invading_VBG cytotrophoblasts_NNS initiate_VB expression_NN of_IN adhesion_NN molecules_NNS ,_, such_JJ as_IN integrin_NN alpha1beta1_NN ,_, and_CC proteinases_NNS ,_, which_WDT are_VBP required_VBN for_IN invasion_NN ,_, besides_IN molecules_NNS inducing_VBG maternal_JJ immune_JJ tolerance_NN ,_, such_JJ as_IN HLA-G_NP and_CC interleukin-10_NP ._SENT Additionally_RB ,_, in_IN the_DT process_NN called_VBD pseudovasculogenesis_NN ,_, invading_VBG cells_NNS modify_VB the_DT phenotype_NN of_IN their_PP$ adhesion_NN molecules_NNS ,_, mimicking_VBG that_IN of_IN endothelial_JJ cells_NNS by_IN expressing_VBG alphavbeta3_JJ integrin_NN ,_, a_DT marker_NN of_IN angiogenic_JJ endothelium_NN ,_, and_CC vascular_JJ endothelial_JJ cadherin_NN ,_, a_DT marker_NN of_IN cell_NN polarization_NN ._SENT That_DT placenta_NN behaves_VBZ as_IN a_DT reservoir_NN in_IN which_WDT HCMV_NP replicates_VBZ prior_RB to_TO being_VBG transmitted_VBN to_TO the_DT fetus_NN has_VBZ been_VBN experimentally_RB shown_VBN in_IN the_DT guinea_NN pig_NN ,_, which_WDT ,_, as_IN in_IN humans_NNS ,_, has_VBZ a_DT hemomonochorial_JJ placenta_NN with_IN a_DT single_JJ trophoblast_NN layer_NN separating_VBG fetal_JJ from_IN maternal_JJ circulation_NN ._SENT In_IN experimental_JJ infection_NN of_IN the_DT guinea_NN pig_NN with_IN species-specific_JJ CMV_NP ,_, the_DT virus_NN disseminates_VBZ hematogenously_RB to_TO the_DT placenta_NN ,_, from_IN which_WDT it_PP is_VBZ transmitted_VBN to_TO the_DT fetus_NN in_IN about_RB 25_CD %_NN of_IN cases_NNS ._SENT The_DT guinea_NN pig_NN CMV_NP also_RB persists_VBZ in_IN placental_JJ tissues_NNS long_RB after_IN virus_NN has_VBZ been_VBN cleared_VBN from_IN blood_NN ._SENT Recently_RB ,_, a_DT greater_JJR understanding_NN of_IN the_DT human_JJ placenta_NN has_VBZ been_VBN achieved_VBN by_IN using_VBG two_CD in_IN vitro_NN models_NNS for_IN the_DT study_NN of_IN trophoblast_NN populations_NNS lying_VBG at_IN the_DT maternal-fetal_JJ interface_NN ,_, villous_JJ explants_NNS and_CC isolated_JJ cytotrophoblasts_NNS (_( -_: )_) ._SENT These_DT data_NNS ,_, coupled_VBN with_IN immunohistochemical_JJ studies_NNS of_IN in_IN vivo_JJ HCMV-infected_JJ placentas_NNS and_CC recent_JJ findings_NNS on_IN HCMV_NP latency_NN ,_, have_VBP led_VBN to_TO new_JJ hypotheses_NNS for_IN routes_NNS of_IN transmission_NN of_IN HCMV_NP to_TO the_DT fetus_NN in_IN primary_JJ and_CC reactivated_VBN maternal_JJ HCMV_NP infection_NN ._SENT During_IN primary_JJ infection_NN of_IN the_DT mother_NN ,_, leukocytes_NNS carrying_VBG infectious_JJ virus_NN may_MD transmit_VB HCMV_NP infection_NN to_TO uterine_JJ microvascular_JJ endothelial_JJ cells_NNS (_( E._NP Maidji_NP ,_, E._NP Percivalle_NP ,_, G._NP Gerna_NP ,_, S._NP Fisher_NP ,_, and_CC L._NP Pereira_NP ,_, Abstr_NP ._SENT 8th_JJ International_NP Cytomegalovirus_NP Workshop_NP ,_, abstr_NP ._SENT p._NN 31_CD ,_, 2001_CD )_) ._SENT These_DT cells_NNS are_VBP in_IN direct_JJ contact_NN with_IN cytotrophoblasts_NNS of_IN anchoring_VBG villi_NNS invading_VBG maternal_JJ arterioles_NNS and_CC forming_VBG hybrids_NNS of_IN maternal-fetal_JJ cells_NNS ._SENT Infected_JJ cytotrophoblasts_NNS may_MD in_RB turn_VB transmit_VB the_DT infection_NN to_TO underlying_VBG tissues_NNS of_IN villous_JJ cores_NNS ,_, including_VBG fibroblasts_NNS and_CC fetal_JJ endothelial_JJ cells_NNS ,_, thus_RB spreading_VBG to_TO the_DT fetus_NN ._SENT An_DT alternative_JJ model_NN of_IN transmission_NN ,_, in_IN the_DT case_NN of_IN primary_JJ maternal_JJ infection_NN ,_, is_VBZ spreading_VBG of_IN infection_NN to_TO the_DT villous_JJ stroma_NN by_IN infected_JJ maternal_JJ leukocytes_NNS through_IN breaches_NNS of_IN the_DT syncytiotrophoblast_NN layer_NN ._SENT A_DT further_JJR hypothesis_NN has_VBZ been_VBN raised_VBN suggesting_VBG possible_JJ transportation_NN of_IN the_DT virus_NN as_IN antibody-coated_JJ HCMV_NP virions_NNS by_IN a_DT process_NN of_IN transcytosis_NN through_IN intact_JJ syncytiotrophoblasts_NNS similar_JJ to_TO that_DT advocated_VBN for_IN transport_NN of_IN maternal_JJ IgG_NP to_TO the_DT fetus_NN ._SENT Finally_RB ,_, syncytiotrophoblasts_NNS may_MD be_VB directly_RB infected_VBN ,_, but_CC the_DT infection_NN proceeds_NNS slowly_RB and_CC remains_VBZ predominantly_RB cell_NN associated_VBN until_IN infected_JJ cells_NNS are_VBP eliminated_VBN during_IN the_DT physiological_JJ turnover_NN ._SENT This_DT hypothesis_NN therefore_RB excludes_VBZ transmission_NN through_IN virus_NN replication_NN in_IN syncytiotrophoblasts_NNS ._SENT In_IN the_DT case_NN of_IN congenital_JJ HCMV_NP infection_NN following_VBG recurrent_JJ maternal_JJ infection_NN ,_, it_PP must_MD be_VB considered_VBN that_IN the_DT placenta_NN is_VBZ a_DT hemiallograft_NN inducing_VBG local_JJ immunosuppression_NN in_IN the_DT uterus_NN ._SENT This_DT may_MD cause_VB reactivation_NN of_IN latent_JJ virus_NN in_IN macrophages_NNS of_IN the_DT uterine_JJ wall_NN ,_, with_IN HCMV_NP transmission_NN to_TO the_DT invading_VBG cytotrophoblasts_NNS ._SENT Then_RB ,_, virus_NN could_MD spread_VB in_IN a_DT retrograde_JJ manner_NN to_TO anchoring_VBG villi_NNS and_CC subsequently_RB to_TO the_DT fetus_NN ._SENT In_IN this_DT regard_NN ,_, HCMV_NP establishes_VBZ a_DT true_JJ latent_JJ infection_NN in_IN CD14+_NP monocytes_NNS ,_, which_WDT can_MD be_VB reactivated_VBN upon_IN allogeneic_JJ stimulation_NN of_IN monocyte-derived_JJ macrophages_NNS from_IN healthy_JJ blood_NN donors_NNS ._SENT Reactivation_NN of_IN latent_JJ HCMV_NP is_VBZ dependent_JJ on_IN the_DT production_NN of_IN gamma_NN interferon_NN in_IN the_DT differentiation_NN process_NN ._SENT These_DT data_NNS await_VBP confirmation_NN by_IN other_JJ laboratories_NNS ._SENT As_IN a_DT consequence_NN of_IN placental_JJ infection_NN ,_, HCMV_NP impairs_VBZ cytotrophoblast_NN differentiation_NN and_CC invasiveness_NN ,_, as_RB shown_VBN in_IN vitro_NN ._SENT This_DT could_MD explain_VB early_JJ abortion_NN occurring_VBG in_IN women_NNS with_IN primary_JJ infection_NN ._SENT In_IN addition_NN ,_, HCMV_NP infection_NN impairs_VBZ cytotrophoblast_NN expression_NN of_IN HLA-G_NP ,_, thus_RB activating_VBG the_DT maternal_JJ immune_JJ response_NN against_IN the_DT cytotrophoblast_NN subpopulation_NN expressing_VBG this_DT molecule_NN ._SENT FIG._NN 3_CD ._SENT |_SYM Diagram_NP of_IN a_DT longitudinal_JJ section_NN that_WDT includes_VBZ a_DT floating_JJ and_CC an_DT anchoring_VBG chorionic_JJ villus_NN at_IN the_DT fetal-maternal_JJ interface_NN near_IN the_DT end_NN of_IN the_DT first_JJ trimester_NN of_IN human_JJ pregnancy_NN ._SENT Diagram_NN of_IN a_DT longitudinal_JJ section_NN that_WDT includes_VBZ a_DT floating_JJ and_CC an_DT anchoring_VBG chorionic_JJ villus_NN at_IN the_DT fetal-maternal_JJ interface_NN near_IN the_DT end_NN of_IN the_DT first_JJ trimester_NN of_IN human_JJ pregnancy_NN ._SENT The_DT anchoring_VBG villus_NN (_( AV_NP )_) functions_NNS as_IN a_DT bridge_NN between_IN the_DT fetal_JJ and_CC maternal_JJ compartments_NNS ,_, whereas_IN the_DT floating_JJ villus_NN (_( FV_NP )_) ,_, containing_VBG macrophages_NNS (_( Mp_NP ,_, Hofbauer_NP cells_NNS )_) and_CC fetal_JJ blood_NN vessels_NNS ,_, is_VBZ bathed_VBN by_IN maternal_JJ blood_NN ._SENT Cytotrophoblasts_NNS in_IN the_DT anchoring_VBG villus_NN (_( zone_NN I_CD )_) form_NN cell_NN columns_NNS that_WDT attach_VBP to_TO the_DT uterine_JJ wall_NN (_( zones_NNS II_NP and_CC III_NP )_) ._SENT Cytotrophoblasts_NNS then_RB invade_VBP the_DT uterine_JJ interstitium_NN (_( decidua_NN and_CC first_RB third_JJ of_IN the_DT myometrium_NN ;_: zone_NN IV_CD )_) and_CC maternal_JJ vasculature_NN (_( zone_NN V_CD )_) ,_, thereby_RB anchoring_VBG the_DT fetus_NN to_TO the_DT mother_NN and_CC accessing_VBG the_DT maternal_JJ circulation_NN ._SENT Zone_NN designations_NNS mark_VBP areas_NNS in_IN which_WDT cytotrophoblasts_NNS have_VBP distinct_JJ patterns_NNS of_IN stage-specific_JJ antigen_NN expression_NN ,_, including_VBG integrin_NP and_CC HLA-G_NP ._SENT Decidual_JJ granular_JJ leukocytes_NNS (_( DGLs_NP )_) and_CC macrophages_NNS (_( Mp_NN )_) in_IN maternal_JJ blood_NN and_CC fetal_JJ capillaries_NNS in_IN villous_JJ cores_NNS are_VBP indicated_VBN ._SENT Areas_NNS proposed_VBN as_IN sites_NNS of_IN natural_JJ HCMV_NP transmission_NN to_TO the_DT placenta_NN in_IN utero_NP are_VBP numbered_VBN 1_CD ,_, 2_CD ,_, and_CC 3_CD ._SENT (_( From_IN Fisher_NP et_FW al._FW ,_, used_VBN with_IN permission_NN ._SENT )_) By_IN far_RB the_DT major_JJ role_NN in_IN transmitting_VBG HCMV_NP infection_NN to_TO the_DT fetus_NN is_VBZ played_VBN by_IN primary_JJ infections_NNS of_IN the_DT mother_NN during_IN pregnancy_NN ._SENT In_IN fact_NN ,_, the_DT rate_NN of_IN vertical_JJ transmission_NN was_VBD found_VBN to_TO be_VB 0.2_CD to_TO 2.2_CD %_NN in_IN previously_RB seropositive_JJ mothers_NNS undergoing_VBG recurrent_JJ infection_NN during_IN pregnancy_NN and_CC 20_CD to_TO 40_CD %_NN in_IN pregnant_JJ women_NNS with_IN primary_JJ infection_NN ._SENT Thus_RB ,_, the_DT ratio_NN of_IN transmitting_VBG to_TO nontransmitting_JJ mothers_NNS is_VBZ on_IN the_DT order_NN of_IN 1:100_CD between_IN those_DT with_IN recurrent_JJ and_CC those_DT with_IN primary_JJ infection_NN ._SENT In_IN this_DT respect_NN ,_, diagnosis_NN of_IN primary_JJ infection_NN during_IN pregnancy_NN is_VBZ a_DT major_JJ task_NN of_IN the_DT diagnostic_JJ virology_NN laboratory_NN ._SENT It_PP may_MD be_VB achieved_VBN in_IN the_DT majority_NN of_IN cases_NNS through_IN concurrent_JJ analysis_NN of_IN the_DT following_VBG factors_NNS :_: serum_NN antibodies_NNS ,_, virus_NN detection_NN in_IN blood_NN ,_, and_CC clinical_JJ signs_NNS and_CC symptoms_NNS ._SENT Seroconversion_NN ._SENT |_SYM The_DT diagnosis_NN of_IN primary_JJ HCMV_NP infection_NN is_VBZ ascertained_VBN when_WRB seroconversion_NN is_VBZ documented_VBN ,_, i.e._FW ,_, the_DT de_NP novo_NN appearance_NN of_IN virus-specific_JJ IgG_NP in_IN the_DT serum_NN of_IN a_DT pregnant_JJ woman_NN who_WP was_VBD previously_RB seronegative_JJ ._SENT However_RB ,_, such_PDT an_DT approach_NN is_VBZ feasible_JJ only_RB when_WRB a_DT screening_NN program_NN is_VBZ adopted_VBN and_CC seronegative_JJ women_NNS are_VBP identified_VBN and_CC prospectively_RB monitored_VBN ._SENT In_IN this_DT respect_NN ,_, screening_VBG programs_NNS are_VBP not_RB approved_VBN by_IN public_JJ health_NN authorities_NNS of_IN the_DT great_JJ majority_NN of_IN developed_JJ countries_NNS ,_, as_RB reported_VBN elsewhere_RB (_( see_VB Universal_NP Serology_NP Screening_NP )_) ._SENT Thus_RB ,_, detection_NN of_IN HCMV-specific_JJ antibodies_NNS or_CC IgG_NP in_IN the_DT blood_NN of_IN a_DT pregnant_JJ woman_NN in_IN the_DT absence_NN of_IN prepregnancy_NN antibody_NN determination_NN does_VBZ not_RB lead_VB to_TO suspicion_NN of_IN primary_JJ infection_NN ._SENT HCMV-specific_NP IgM_NP antibody_NN must_MD be_VB determined_VBN for_IN this_DT purpose_NN ._SENT Although_IN detection_NN of_IN specific_JJ IgM_NP is_VBZ not_RB sufficient_JJ per_IN se_FW to_TO diagnose_VB primary_JJ HCMV_NP infection_NN (_( IgM_NP can_MD also_RB be_VB detected_VBN during_IN reactivations_NNS )_) ,_, primary_JJ infection_NN is_VBZ consistently_RB associated_VBN with_IN the_DT presence_NN of_IN a_DT virus-specific_JJ IgM_NP antibody_NN response_NN ._SENT Several_JJ serologic_JJ assays_NNS have_VBP been_VBN used_VBN in_IN the_DT past_NN to_TO detect_VB HCMV-specific_NP IgM_NP antibodies_NNS both_CC in_IN whole_JJ serum_NN and_CC serum_NN fractions_NNS obtained_VBN by_IN sucrose_NN density_NN gradient_JJ centrifugation_NN or_CC column_NN chromatography_NN ._SENT These_DT include_VBP complement_NN fixation_NN ,_, anticomplement_NN immunofluorescence_NN ,_, indirect_JJ hemagglutination_NN ,_, and_CC radioimmunoassay_NN ._SENT More_RBR recently_RB ,_, enzyme-linked_JJ immunosorbent_JJ assays_NNS (_( ELISAs_NP )_) have_VBP been_VBN more_RBR widely_RB used_VBN in_IN both_CC the_DT indirect_JJ ELISA_NP and_CC the_DT capture_NN ELISA_NP format_NN with_IN either_DT labeled_VBN antigen_NN or_CC antibody_NN ._SENT The_DT indirect_JJ ELISA_NP shows_VBZ the_DT following_VBG potential_JJ sources_NNS of_IN error_NN when_WRB performed_VBN on_IN whole_JJ serum_NN :_: (_( i_NP )_) competitive_JJ inhibition_NN due_JJ to_TO the_DT presence_NN of_IN specific_JJ IgG_NP ;_: (_( ii_NP )_) interference_NN due_JJ to_TO rheumatoid_JJ factor_NN of_IN the_DT IgM_NP class_NN (_( IgM-RF_NP )_) or_CC to_TO IgM-RF_NP reactive_JJ only_RB with_IN autologous_JJ complexed_JJ IgG_NP ;_: and_CC (_( iii_NN )_) interference_NN due_JJ to_TO IgM_NP antibody_NN reactive_JJ with_IN cellular_JJ antigens_NNS ._SENT All_PDT these_DT interfering_VBG factors_NNS could_MD be_VB readily_RB eliminated_VBN by_IN mixing_VBG serum_NN samples_NNS with_IN anti-human_NN gamma_NN chain_NN serum_NN ._SENT However_RB ,_, following_VBG the_DT development_NN of_IN ELISA_NP technology_NN ,_, most_RBS initial_JJ IgM_NP indirect_JJ ELISAs_NP were_VBD replaced_VBN by_IN IgM_NP capture_NN assays_NNS based_VBN on_IN selective_JJ binding_NN of_IN IgM_NP antibody_NN to_TO the_DT solid_JJ phase_NN ._SENT In_IN capture_NN ELISAs_NNS ,_, while_IN IgG_NP does_VBZ not_RB interfere_VB ,_, IgM-RF_NP may_MD cause_VB false_JJ results_NNS by_IN competing_VBG with_IN viral_JJ IgM_NP for_IN anti-IgM_NP binding_VBG sites_NNS on_IN the_DT solid_JJ phase_NN ,_, complexing_VBG with_IN specific_JJ IgG_NP ,_, which_WDT in_IN turn_NN binds_VBZ viral_JJ antigens_NNS ,_, reacting_VBG directly_RB with_IN the_DT labeled_VBN viral_JJ antibody_NN ,_, and_CC mutual_JJ interference_NN with_IN antinuclear_JJ antibody_NN ._SENT More_RBR precisely_RB ,_, in_IN capture_NN ELISAs_NP ,_, the_DT presence_NN of_IN the_DT sole_JJ IgM-RF_NP (_( or_CC IgG-RF_NP )_) does_VBZ not_RB cause_VB false-positive_JJ results_NNS ,_, which_WDT have_VBP been_VBN observed_VBN to_TO occur_VB in_IN serum_NN samples_NNS containing_VBG both_DT IgM-RF_NP and_CC IgG-antinuclear_NP antibody_NN ._SENT Initially_RB ,_, capture_VB ELISAs_NNS with_IN enzyme-labeled_JJ antigen_NN appeared_VBD to_TO be_VB the_DT most_RBS promising_JJ assays_NNS ._SENT However_RB ,_, after_IN a_DT few_JJ years_NNS ,_, it_PP was_VBD recommended_VBN ,_, for_IN specificity_NN control_NN of_IN test_NN results_NNS ,_, that_DT human_JJ serum_NN samples_NNS be_VB tested_VBN in_IN parallel_NN with_IN viral_JJ and_CC cell_NN control_NN labeled_VBN antigens_NNS ._SENT In_IN addition_NN ,_, false-positive_JJ results_NNS due_JJ to_TO the_DT presence_NN of_IN both_DT RF_NP and_CC antinuclear_JJ antibody_NN ,_, as_RB reported_VBD above_IN ,_, could_MD be_VB avoided_VBN in_IN capture_NN ELISAs_NNS employing_VBG labeled_VBN F(ab')2_JJ fragments_NNS of_IN specific_JJ antibody_NN instead_RB of_IN the_DT IgG_NP fraction_NN ._SENT In_IN order_NN to_TO avoid_VB false-positive_JJ results_NNS ,_, we_PP developed_VBD a_DT capture_NN ELISA_NP IgM_NP assay_NN with_IN a_DT mixture_NN of_IN viral_JJ antigen_NN and_CC mouse_NN monoclonal_NN antibody_NN to_TO the_DT nonstructural_JJ HCMV_NP major_JJ DNA-binding_NP proteins_NNS (_( pp52_NN or_CC ppUL44_NN )_) as_IN a_DT detector_NN system_NN ._SENT This_DT phosphoprotein_NN is_VBZ prominent_JJ in_IN HCMV-infected_JJ cells_NNS and_CC is_VBZ known_VBN to_TO be_VB recognized_VBN primarily_RB by_IN human_JJ IgM_NP during_IN the_DT convalescent_JJ phase_NN of_IN a_DT primary_JJ HCMV_NP infection_NN ._SENT According_VBG to_TO this_DT approach_NN ,_, antinuclear_JJ antibody_NN of_IN the_DT IgM_NP class_NN bound_VBN to_TO the_DT solid_JJ phase_NN will_MD not_RB give_VB false_JJ reactions_NNS because_IN only_JJ IgM_NP antibody_NN reactive_JJ to_TO pp52_NN are_VBP recognized_VBN by_IN the_DT specific_JJ monoclonal_NN antibody_NN ._SENT Different_JJ levels_NNS of_IN specificity_NN were_VBD determined_VBN with_IN this_DT assay_NN ._SENT General_JJ specificity_NN ,_, determined_VBN on_IN a_DT series_NN of_IN unselected_JJ IgM-negative_NP serum_NN samples_NNS from_IN an_DT adult_JJ population_NN ,_, was_VBD 100_CD %_NN ._SENT Stringent_JJ specificity_NN ,_, evaluated_VBN on_IN a_DT series_NN of_IN potentially_RB interfering_VBG serum_NN samples_NNS from_IN patients_NNS who_WP had_VBD Epstein-Barr_NP virus-related_JJ infectious_JJ mononucleosis_NN ,_, autoimmune_JJ diseases_NNS ,_, or_CC rheumatoid_JJ factor_NN or_CC who_WP had_VBD been_VBN treated_VBN with_IN radioimmunotherapy_NN based_VBN on_IN the_DT use_NN of_IN mouse_NN monoclonal_NN antibody_NN ,_, was_VBD 96.3_CD %_NN ._SENT Finally_RB ,_, clinical_JJ specificity_NN ,_, determined_VBN on_IN a_DT series_NN of_IN IgM-negative_NP serum_NN samples_NNS drawn_VBN prior_RB to_TO onset_NN of_IN primary_JJ HCMV_NP infection_NN ,_, was_VBD 100_CD %_NN ._SENT Thus_RB ,_, the_DT overall_JJ specificity_NN was_VBD 98.9_CD %_NN (_( 363_CD of_IN 367_CD IgM-negative_NP serum_NN samples_NNS tested_VBD )_) ._SENT The_DT sensitivity_NN ,_, assayed_VBN on_IN 277_CD IgM-positive_NP serum_NN samples_NNS ,_, was_VBD 100_CD %_NN ._SENT Comparison_NN of_IN the_DT results_NNS obtained_VBN by_IN this_DT assay_NN with_IN those_DT given_VBN by_IN enzyme-labeled_JJ antigen_NN showed_VBD that_IN the_DT HCMV_NP p52-specific_JJ IgM_NP antibody_NN response_NN paralleled_VBD that_IN obtained_VBN by_IN using_VBG enzyme-labeled_JJ antigen_NN ,_, thus_RB representing_VBG a_DT major_JJ component_NN of_IN it_PP ,_, i.e._FW ,_, a_DT major_JJ part_NN of_IN the_DT antibody_NN response_NN within_IN the_DT IgM_NP class_NN ._SENT In_IN addition_NN ,_, this_DT study_NN showed_VBD that_IN ,_, while_IN HCMV-specific_NP IgM_NP drops_VBZ sharply_RB in_IN titer_NN in_IN normal_JJ subjects_NNS within_IN 2_CD to_TO 3_CD months_NNS after_IN onset_NN of_IN infection_NN and_CC is_VBZ virtually_RB undetectable_JJ within_IN 12_CD months_NNS ,_, in_IN immunocompromised_JJ patients_NNS such_PDT a_DT response_NN persists_VBZ much_RB longer_RBR ._SENT Thus_RB ,_, in_IN pregnant_JJ women_NNS ,_, detection_NN of_IN HCMV_NP IgM_NP antibody_NN may_MD be_VB related_VBN to_TO a_DT primary_JJ infection_NN occurring_VBG during_IN pregnancy_NN when_WRB the_DT IgM_NP titer_NN falls_VBZ sharply_RB in_IN sequential_JJ blood_NN samples_NNS ._SENT The_DT presence_NN of_IN low_JJ ,_, slowly_RB decreasing_VBG levels_NNS of_IN IgM_NP may_MD indicate_VB a_DT primary_JJ infection_NN initiated_VBD some_DT months_NNS earlier_RBR and_CC possibly_RB prior_JJ to_TO pregnancy_NN ._SENT These_DT findings_NNS are_VBP basically_RB in_IN agreement_NN with_IN previous_JJ reports_NNS describing_VBG a_DT broad_JJ HCMV_NP IgM_NP antibody_NN response_NN ._SENT An_DT additional_JJ risk_NN of_IN HCMV_NP IgM_NP ELISA_NP is_VBZ a_DT false-positive_JJ result_NN due_JJ to_TO primary_JJ Epstein-Barr_NP virus_NN infection_NN acting_VBG as_IN a_DT potent_JJ B-cell_NN stimulator_NN and_CC resulting_VBG in_IN the_DT production_NN of_IN HCMV_NP IgM_NP antibody_NN in_IN HCMV-immune_NP individuals_NNS ._SENT Dual_JJ HCMV_NP and_CC Epstein-Barr_NP virus_NN infection_NN has_VBZ also_RB been_VBN reported_VBN ._SENT Besides_IN the_DT lack_NN of_IN standards_NNS for_IN HCMV_NP IgM_NP serology_NN ,_, the_DT high_JJ level_NN of_IN discordance_NN among_IN commercial_JJ assays_NNS for_IN detection_NN of_IN HCMV-specific_NP IgM_NP has_VBZ been_VBN attributed_VBN to_TO the_DT lack_NN of_IN standardization_NN of_IN the_DT viral_JJ preparations_NNS used_VBD ._SENT More_RBR recently_RB ,_, in_IN an_DT attempt_NN to_TO improve_VB the_DT specificity_NN of_IN conventional_JJ ELISAs_NNS and_CC to_TO overcome_VB the_DT discordant_JJ results_NNS given_VBN by_IN commercial_JJ kits_NNS based_VBN on_IN use_NN of_IN crude_JJ viral_JJ preparations_NNS ,_, HCMV_NP IgM_NP immunoassays_NNS have_VBP been_VBN developed_VBN based_VBN on_IN recombinant_JJ HCMV_NP proteins_NNS or_CC peptides_NNS ._SENT The_DT HCMV-coded_JJ proteins_NNS reactive_JJ with_IN IgM_NP antibody_NN are_VBP both_DT structural_JJ and_CC nonstructural_JJ ._SENT Major_JJ structural_JJ proteins_NNS include_VBP pp150_NP (_( UL32_NP )_) ,_, pp65_NP (_( UL83_NP )_) ,_, and_CC pp38_NP (_( UL80a_NP )_) ,_, while_IN nonstructural_JJ proteins_NNS include_VBP pp52_NN (_( UL44_NP )_) and_CC p130_JJ (_( UL57_JJ )_) ._SENT Vornhagen_NP et_FW al._FW developed_VBD a_DT recombinant_JJ HCMV_NP IgM_NP ELISA_NP for_IN Biotest_NP (_( Biotest_NP AG_NP ,_, Dreieich_NP ,_, Germany_NP )_) with_IN only_JJ peptides_NNS derived_VBN from_IN nonstructural_JJ proteins_NNS pp52_NN (_( amino_NN acids_NNS 297_CD to_TO 433_CD )_) and_CC p130_JJ (_( amino_NN acids_NNS 545_CD to_TO 601_CD )_) ._SENT In_IN particular_JJ ,_, it_PP was_VBD found_VBN that_IN the_DT indicated_JJ portion_NN of_IN the_DT UL57_JJ gene_NN product_NN is_VBZ a_DT dominant_JJ IgM_NP antigen_NN which_WDT may_MD be_VB superior_JJ in_IN both_DT sensitivity_NN and_CC specificity_NN to_TO fragments_NNS from_IN other_JJ HCMV_NP proteins_NNS for_IN detection_NN of_IN IgM_NP antibodies_NNS during_IN primary_JJ HCMV_NP infection_NN ._SENT Recombinant_JJ proteins_NNS and_CC their_PP$ fragments_NNS have_VBP been_VBN studied_VBN in_IN a_DT Western_JJ blot_NN or_CC immunoblot_NN assay_NN for_IN their_PP$ reactivity_NN to_TO IgM-positive_VB serum_NN samples_NNS prior_RB to_TO being_VBG included_VBN in_IN an_DT ELISA_NP ._SENT The_DT group_NN of_IN M._NP P._NP Landini_NP ,_, in_IN close_JJ association_NN with_IN Abbott_NP Laboratories_NPS (_( Abbott_NP Park_NP ,_, Ill._NP )_) ,_, developed_VBD two_CD versions_NNS of_IN the_DT HCMV_NP IgM_NP immunoblot_NN assay_NN with_IN both_DT recombinant_JJ proteins_NNS or_CC peptides_NNS and_CC viral_JJ proteins_NNS from_IN purified_VBN virus_NN preparations_NNS ._SENT In_IN the_DT new_JJ version_NN of_IN the_DT assay_NN ,_, the_DT viral_JJ section_NN of_IN a_DT slot_NN blot_NN contains_VBZ the_DT entire_JJ viral_JJ proteins_NNS pp150_NN (_( UL32_NP )_) ,_, pp82_NN ,_, pp65_NP (_( UL83_NP )_) ,_, and_CC pp28_NP (_( UL99_NP )_) purified_VBD by_IN gel_NN electrophoresis_NN ,_, while_IN the_DT recombinant_JJ section_NN contains_VBZ only_JJ portions_NNS of_IN pp150_NN (_( amino_NN acids_NNS 595_CD to_TO 614_CD and_CC 1006_CD to_TO 1048_CD )_) ,_, p130_JJ (_( amino_NN acids_NNS 545_CD to_TO 601_CD and_CC 1144_CD to_TO 1233_CD )_) ,_, pp52_JJ (_( amino_NN acids_NNS 202_CD to_TO 434_CD )_) ,_, and_CC pp38_JJ (_( amino_NN acids_NNS 117_CD to_TO 383_CD )_) ._SENT A_DT preliminary_JJ evaluation_NN of_IN the_DT new_JJ immunoblot_NN assay_NN indicated_VBD that_IN 13_CD of_IN 80_CD (_( 16_CD %_NN )_) IgG-_NP and_CC IgM-negative_NP serum_NN samples_NNS and_CC as_RB many_JJ as_IN 38_CD of_IN 200_CD (_( 19_CD %_NN )_) IgG-positive_NP ,_, IgM-negative_NP serum_NN samples_NNS did_VBD react_VB with_IN one_CD or_CC more_JJR of_IN the_DT viral_JJ or_CC recombinant_JJ proteins_NNS ,_, while_IN 126_CD of_IN 126_CD (_( 100_CD %_NN )_) IgM-positive_NP serum_NN samples_NNS reacted_VBD variably_RB ._SENT In_IN order_NN to_TO render_VB these_DT highly_RB nonspecific_JJ results_NNS interpretable_JJ ,_, an_DT algorithm_NN for_IN reading_NN of_IN test_NN results_NNS had_VBD to_TO be_VB introduced_VBN ._SENT Thus_RB ,_, only_JJ serum_NN samples_NNS reactive_JJ with_IN at_IN least_JJS one_CD viral_JJ and_CC one_CD recombinant_JJ protein_NN or_CC serum_NN samples_NNS reactive_JJ with_IN at_IN least_JJS three_CD recombinant_JJ protein_NN bands_NNS were_VBD considered_VBN positive_JJ for_IN IgM_NP ._SENT By_IN using_VBG this_DT approach_NN ,_, a_DT sensitivity_NN of_IN 100_CD %_NN and_CC specificity_NN of_IN 98.6_CD %_NN were_VBD reached_VBN with_IN respect_NN to_TO the_DT consensus_NN of_IN two_CD of_IN the_DT most_RBS used_VBN commercial_JJ ELISAs_NP (_( Behring_NP AG_NP ,_, Marburg_NP ,_, Germany_NP ,_, and_CC DiaSorin_NP ,_, Saluggia_NP ,_, Italy_NP )_) ._SENT This_DT assay_NN was_VBD used_VBN as_IN a_DT reference_NN test_NN for_IN development_NN of_IN the_DT Abbott_NP AxSYM_NP CMV_NP IgM_NP microparticle_NN enzyme_NN immunoassay_NN ,_, with_IN microparticles_NNS coated_VBN with_IN the_DT indicated_JJ portions_NNS of_IN three_CD structural_JJ (_( pp150_NP ,_, amino_NN acids_NNS 595_CD to_TO 614_CD and_CC 1006_CD to_TO 1048_CD ;_: pp65_NN ,_, amino_NN acids_NNS 297_CD to_TO 510_CD ;_: and_CC pp38_NN ,_, amino_NN acids_NNS 117_CD to_TO 373_CD )_) and_CC one_CD nonstructural_JJ (_( p52_JJ ,_, amino_NN acids_NNS 202_CD to_TO 434_CD )_) protein_NN ._SENT This_DT assay_NN ,_, when_WRB compared_VBN to_TO a_DT consensus_NN given_VBN by_IN three_CD commercial_JJ HCMV_NP IgM_NP immunoassays_NNS (_( discordant_JJ results_NNS were_VBD resolved_VBN by_IN immunoblot_NN )_) ,_, showed_VBD a_DT relative_JJ sensitivity_NN ,_, specificity_NN ,_, and_CC agreement_NN of_IN greater_JJR than_IN 95_CD %_NN ._SENT In_IN addition_NN ,_, the_DT assay_NN was_VBD able_JJ to_TO detect_VB seroconversion_NN very_RB early_RB and_CC displayed_VBD a_DT higher_JJR positive_JJ reactivity_NN rate_NN than_IN the_DT commercial_JJ assays_NNS tested_VBN on_IN pregnant_JJ women_NNS ._SENT The_DT level_NN of_IN cross-reactivity_NN was_VBD 3.3_CD %_NN ._SENT The_DT diagnostic_JJ utility_NN of_IN the_DT AxSYM_NP IgM_NP assay_NN in_IN detecting_VBG low_JJ levels_NNS of_IN IgM_NP antibody_NN (_( not_RB detected_VBN by_IN other_JJ commercial_JJ assays_NNS )_) in_IN some_DT serum_NN samples_NNS is_VBZ stressed_VBN by_IN the_DT finding_NN that_IN some_DT of_IN these_DT serum_NN samples_NNS contain_VBP low-avidity_NN IgG_NP ,_, a_DT marker_NN of_IN primary_JJ HCMV_NP infection_NN (_( see_VB IgG_NP Avidity_NP Assay_NP )_) ._SENT At_IN least_JJS one_CD additional_JJ approach_NN has_VBZ been_VBN reported_VBN ,_, with_IN a_DT combination_NN of_IN two_CD HCMV_NP peptides_NNS derived_VBN from_IN pp150_NN (_( UL32_NP ,_, amino_NN acids_NNS 1011_CD to_TO 1048_CD )_) and_CC pp52_JJ (_( UL44_NP ,_, amino_NN acids_NNS 266_CD to_TO 293_CD )_) for_IN IgM_NP detection_NN and_CC a_DT combination_NN of_IN peptides_NNS from_IN pp150_NN (_( amino_NN acids_NNS 1011_CD to_TO 1048_CD )_) ,_, pp28_JJ (_( amino_NN acids_NNS 130_CD to_TO 160_CD )_) ,_, and_CC gB_NN (_( amino_NN acids_NNS 60_CD to_TO 81_CD )_) for_IN optimal_JJ IgG_NP detection_NN ._SENT Sensitivity_NN was_VBD 96.4_CD %_NN for_IN the_DT IgM_NP assay_NN with_IN respect_NN to_TO a_DT viral_JJ lysate-based_JJ ELISA_NP ._SENT Although_IN the_DT development_NN of_IN immunoassays_NNS based_VBN on_IN use_NN of_IN recombinant_JJ viral_JJ proteins_NNS or_CC peptide_NN epitopes_NNS represents_VBZ major_JJ progress_NN towards_IN standardization_NN of_IN serological_JJ assays_NNS ,_, these_DT assays_NNS do_VBP not_RB appear_VB to_TO be_VB reliable_JJ from_IN the_DT diagnostic_JJ standpoint_NN due_JJ to_TO exceedingly_RB high_JJ sensitivity_NN and_CC somewhat_RB low_JJ specificity_NN ._SENT In_IN a_DT recent_JJ study_NN ,_, 10_CD of_IN 42_CD (_( 23.8_CD %_NN )_) potentially_RB cross-reactive_JJ or_CC interfering_VBG serum_NN samples_NNS were_VBD scored_VBN IgM-positive_NP with_IN a_DT commercial_JJ ELISA_NN based_VBN on_IN use_NN of_IN recombinant_JJ HCMV_NP antigens_NNS ,_, whereas_IN two_CD commercial_JJ ELISAs_NNS based_VBN on_IN use_NN of_IN viral_JJ lysates_NNS detected_VBD zero_CD and_CC one_CD positive_JJ sample_NN ,_, respectively_RB ,_, in_IN the_DT same_JJ panel_NN of_IN problematic_JJ serum_NN samples_NNS ._SENT Indeed_RB ,_, false-positive_JJ results_NNS still_RB represent_VBP the_DT major_JJ pitfall_NN of_IN HCMV_NP IgM_NP serology_NN ._SENT In_IN this_DT respect_NN ,_, in_IN a_DT recent_JJ retrospective_JJ review_NN of_IN 325_CD consecutive_JJ pregnant_JJ women_NNS referred_VBD to_TO our_PP$ laboratory_NN over_IN a_DT 2-year_JJ period_NN because_IN of_IN a_DT positive_JJ IgM_NP result_NN and_CC a_DT suspicion_NN of_IN primary_JJ HCMV_NP infection_NN ,_, as_RB many_JJ as_IN 188_CD (_( 57.8_CD %_NN )_) were_VBD found_VBN to_TO be_VB IgM_NP negative_JJ by_IN two_CD different_JJ in-house-developed_JJ capture_NN ELISAs_NNS in_IN the_DT absence_NN of_IN primary_JJ infection_NN ._SENT Once_RB the_DT specificity_NN of_IN a_DT positive_JJ IgM_NP result_NN has_VBZ been_VBN verified_VBN ,_, the_DT interpretation_NN of_IN the_DT clinical_JJ significance_NN of_IN IgM_NP antibody_NN present_NN in_IN the_DT serum_NN of_IN a_DT pregnant_JJ woman_NN begins_VBZ ._SENT We_PP must_MD recall_VB that_IN the_DT IgM_NP antibody_NN respons_NNS 